NCT04493242View on ClinicalTrials.gov

Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

September 24, 2020

Primary Completion Date

May 1, 2021

Study Completion Date

May 22, 2021

Conditions
COVID-19ARDS
Interventions
BIOLOGICAL

ExoFlo

Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles

OTHER

Intravenous normal saline

Placebo

Trial Locations (6)

18840

Direct Biologics Investigational Site, Sayre

35660

Direct Biologics Investigational Site, Sheffield

75149

Direct Biologics Investigational Site, Mesquite

77024

Direct Biologics Investigational Site, Houston

79410

Direct Biologics Investigational Site, Lubbock

92805

Direct Biologics Investigational Site, Anaheim

Sponsors
All Listed Sponsors
lead

Direct Biologics, LLC

INDUSTRY